Sree Rayalaseema Hi-Strength Hypo (SRHHYPOLTD)₹492.90−0.75%Commodity Chemicals
In the Jun 2026 quarter (consolidated), Sree Rayalaseema Hi-Strength Hypo reported sales of ₹211 Cr, up 17.1% from Jun 2025, and net profit of ₹24.93 Cr, up 13.8% year on year. For the year to Mar 2026, sales were ₹667 Cr and net profit ₹89.62 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 226 | 215 | 165 | 169 | 170 | 138 | 160 | 180 | 182 | 141 | 163 | 211 |
| Expenses | 199 | 192 | 138 | 143 | 141 | 119 | 143 | 152 | 155 | 124 | 150 | 181 |
| Operating Profit | 26.04 | 22.02 | 27.03 | 26.06 | 29.05 | 20.02 | 18.01 | 28.03 | 27.03 | 17.02 | 13.01 | 30.05 |
| OPM % | 11.9% | 9.9% | 15.9% | 14.9% | 16.9% | 14.0% | 10.9% | 15.0% | 14.9% | 11.9% | 8.0% | 13.9% |
| Other Income | 2.01 | 4.01 | 4.01 | 2.01 | 9.03 | 13.04 | 12.04 | 6.02 | 7.02 | 19.05 | 12.04 | 6.02 |
| Interest | 1.01 | 1.01 | 2.01 | 1.01 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 3.01 | 2.99 | 3.01 | 1.99 | 2.01 | 2.01 | 2.01 | 1.99 | 2.01 | 1.99 | 2.01 | 1.99 |
| Profit before tax | 24.96 | 22.96 | 25.94 | 25.96 | 35.93 | 29.95 | 26.94 | 30.93 | 31.94 | 33.94 | 22.95 | 33.94 |
| Tax % | 26.9% | 28.9% | 24.0% | 27.9% | 28.9% | 28.9% | 19.0% | 27.9% | 26.9% | 30.9% | 13.9% | 26.9% |
| Exceptional items | 0.00 | −4.15 | −3.78 | 0.00 | 0.00 | 0.00 | −2.48 | −3.41 | 0.00 | −0.02 | −4.67 | −2.58 |
| Net Profit | 17.95 | 16.94 | 19.94 | 18.93 | 24.92 | 21.93 | 21.93 | 21.91 | 22.93 | 23.92 | 19.92 | 24.93 |
| EPS (Rs) | 10.75 | 9.68 | 11.37 | 10.83 | 14.71 | 12.54 | 12.79 | 12.74 | 13.54 | 13.83 | 11.52 | 14.25 |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 362 | 164 | 689 | 911 | 1,266 | 1,650 | 866 | 638 | 667 | 697 |
| Expenses | 318 | 142 | 588 | 782 | 1,120 | 1,472 | 756 | 547 | 579 | 611 |
| Operating Profit | 44.05 | 22.03 | 102 | 130 | 149 | 180 | 111 | 92.07 | 88.07 | 87.11 |
| OPM % | 11.9% | 12.9% | 14.9% | 13.9% | 11.9% | 10.9% | 12.9% | 13.9% | 12.9% | 12.5% |
| Other Income | 2.01 | 0.00 | 4.01 | 7.02 | 11.03 | 34.09 | 11.02 | 36.12 | 41.13 | 44.13 |
| Interest | 11.04 | 3.01 | 10.04 | 5.02 | 3.01 | 5.02 | 4.02 | 2.01 | 2.01 | 0.00 |
| Depreciation | 10.01 | 10.01 | 49.99 | 51.03 | 18.99 | 19.02 | 11.01 | 7.01 | 7.01 | 8.00 |
| Profit before tax | 24.95 | 8.98 | 44.89 | 80.81 | 137 | 190 | 107 | 119 | 121 | 123 |
| Tax % | 26.9% | −1.0% | 16.9% | 24.9% | 24.9% | 18.9% | 26.0% | 27.0% | 24.9% | — |
| Exceptional items | −0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 12.01 | −7.99 | −2.01 | −10.01 | −7.27 |
| Net Profit | 24.91 | 8.96 | 37.90 | 60.75 | 103 | 154 | 78.77 | 86.72 | 89.62 | 91.70 |
| EPS (Rs) | 16.98 | 5.63 | 22.07 | 35.24 | 59.79 | 89.66 | 45.99 | 52.37 | 51.72 | 53.14 |
| Dividend payout % | 9.1% | 25.1% | 11.0% | 8.0% | 6.0% | 4.0% | 7.0% | 6.0% | 6.0% | — |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14.97 | 14.97 | 16.94 | 16.96 | 16.96 | 16.94 | 16.97 | 16.94 | 16.97 |
| Reserves | 189 | 182 | 294 | 371 | 553 | 734 | 782 | 901 | 953 |
| Borrowings | 84.88 | 78.82 | 56.87 | 71.80 | 27.92 | 18.97 | 12.98 | 15.96 | 11.99 |
| Other Liabilities | 84.05 | 64.30 | 76.07 | 58.81 | 189 | 175 | 100 | 137 | 134 |
| Total Liabilities | 372 | 340 | 445 | 518 | 788 | 945 | 914 | 1,070 | 1,115 |
| Fixed Assets | 195 | 187 | 161 | 134 | 130 | 105 | 128 | 135 | 132 |
| CWIP | 1.99 | 0.00 | 2.99 | 0.00 | 0.00 | 13.98 | 0.00 | 0.00 | 0.00 |
| Investments | 39.13 | 23.06 | 18.05 | 50.15 | 164 | 269 | 254 | 350 | 308 |
| Other Assets | 137 | 129 | 262 | 333 | 493 | 557 | 533 | 584 | 676 |
| Inventories | 22.07 | 12.04 | 37.09 | 40.14 | 144 | 126 | 32.10 | 40.14 | 50.18 |
| Trade receivables | 53.17 | 53.22 | 82.32 | 97.29 | 132 | 150 | 107 | 103 | 84.24 |
| Cash & equivalents | 5.99 | 7.98 | 85.83 | 139 | 113 | 228 | 333 | 373 | 438 |
| Total Assets | 372 | 340 | 445 | 518 | 788 | 945 | 914 | 1,070 | 1,115 |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 21.07 | −8.03 | 99.34 | 71.27 | 60.14 | 141 | 140 | 65.23 | 39.12 |
| Cash from investing activity | −8.97 | −0.99 | −37.88 | −115 | −0.99 | −112 | −19.95 | −7.98 | 36.89 |
| Cash from financing activity | −11.97 | 10.98 | −21.95 | 9.98 | −50.84 | −16.96 | −16.97 | −17.96 | −10.98 |
| Net cash flow | 0.00 | 2.01 | 40.09 | −35.10 | 7.02 | 13.03 | 103 | 40.10 | 65.13 |
| Capex | 6.83 | 1.33 | 8.09 | 20.50 | 14.46 | 8.35 | 20.09 | 2.44 | 6.36 |
| Free cash flow | 14.04 | −9.03 | 91.33 | 50.16 | 45.18 | 133 | 120 | 63.22 | 38.11 |
| CFO / OP % | 63.0% | −35.0% | 108.0% | 82.0% | 62.0% | 122.0% | 152.0% | 105.0% | 74.0% |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 54 | 117 | 43 | 39 | 38 | 33 | 45 | 59 | 46 |
| Inventory days | 38 | 50 | 37 | 28 | 63 | 40 | 25 | 51 | 56 |
| Days payable | 38 | 15 | 23 | 7 | 32 | 21 | 9 | 17 | 12 |
| Cash conversion cycle | 51 | 150 | 55 | 57 | 67 | 50 | 59 | 91 | 88 |
| Working capital days | −1 | 54 | 25 | 24 | 48 | 43 | 60 | 83 | 88 |
| ROCE % | — | 4.0% | — | 21.0% | 26.0% | 26.1% | 15.0% | 14.1% | 14.1% |
For the Jun 2026 quarter, Sree Rayalaseema Hi-Strength Hypo reported sales of ₹211 Cr, up 17.1% year on year and net profit of ₹24.93 Cr, up 13.8% year on year. The operating margin was 13.9%.
Sree Rayalaseema Hi-Strength Hypo's sales for the year to Mar 2026 were ₹667 Cr; over the last twelve months they were ₹697 Cr.
Net profit for the year to Mar 2026 was ₹89.62 Cr, and ₹91.70 Cr over the last twelve months. Earnings per share over the same trailing period were ₹53.14.
Sree Rayalaseema Hi-Strength Hypo reported borrowings of ₹11.99 Cr at Mar 2026, against cash and equivalents of ₹438 Cr.
Cash from operations was ₹39.12 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹38.11 Cr.